NASDAQ:GUTS Fractyl Health (GUTS) Stock Price, News & Analysis $0.89 -0.03 (-3.48%) As of 03:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Fractyl Health Stock (NASDAQ:GUTS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Fractyl Health alerts:Sign Up Key Stats Today's Range$0.88▼$0.9550-Day Range$0.43▼$0.9552-Week Range$0.38▼$3.03Volume1.31 million shsAverage Volume4.30 million shsMarket Capitalization$140.88 millionP/E RatioN/ADividend YieldN/APrice Target$5.40Consensus RatingHold Company Overview Fractyl Health, Inc. is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control. The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine. This outpatient procedure is designed to interrupt disease-driving signals between the gut and the liver, pancreas and brain, with the aim of improving glycemic control and reducing liver fat. Fractyl has conducted multiple clinical trials across North America, Europe and Asia, and holds CE mark approval in the European Union for Revita DMR. Fractyl Health is also developing next-generation therapies and combination approaches to expand the reach of its duodenal resurfacing technology. The company has initiated pivotal studies to support U.S. regulatory filings and is preparing for broader commercial roll-out following anticipated approvals. Fractyl’s management team includes industry veterans in interventional gastroenterology, clinical development and medical device commercialization, positioning the company to address the growing global burden of metabolic disease.AI Generated. May Contain Errors. Read More Fractyl Health Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreGUTS MarketRank™: Fractyl Health scored higher than 69% of companies evaluated by MarketBeat, and ranked 171st out of 858 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingFractyl Health has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialFractyl Health has a consensus price target of $5.40, representing about 488.9% upside from its current price of $0.92.Amount of Analyst CoverageFractyl Health has only been the subject of 3 research reports in the past 90 days.Read more about Fractyl Health's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Fractyl Health are expected to grow in the coming year, from ($0.60) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fractyl Health is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fractyl Health is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFractyl Health has a P/B Ratio of 7.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.07% of the float of Fractyl Health has been sold short.Short Interest Ratio / Days to CoverFractyl Health has a short interest ratio ("days to cover") of 1.61, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fractyl Health has recently decreased by 22.71%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFractyl Health does not currently pay a dividend.Dividend GrowthFractyl Health does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.55 News SentimentFractyl Health has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Fractyl Health this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for GUTS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows2 people have added Fractyl Health to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Fractyl Health insiders have not sold or bought any company stock.Percentage Held by Insiders8.52% of the stock of Fractyl Health is held by insiders.Percentage Held by InstitutionsFractyl Health has minimal institutional ownership at this time.Read more about Fractyl Health's insider trading history. Receive GUTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fractyl Health and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GUTS Stock News HeadlinesFractyl Health Teases Key Revita Data as GLP-1 Weight-Loss ‘Off-Ramp’ NearsMay 20 at 5:39 AM | americanbankingnews.comFractyl Health (GUTS) Is Up 14.0% After First GLP-1 Gene Therapy Trial Win And Profit TurnaroundMay 16, 2026 | finance.yahoo.comJune 12: The Biggest Buying Spree in History?Former tech executive and angel investor Jeff Brown - who picked Bitcoin, Tesla, and Nvidia before surges of up to 52,400% - says the SpaceX IPO on June 12 could trigger the biggest buying spree in market history. Brown is urging investors to get positioned before the IPO date arrives, when shares could double or more on the first day of trading.May 22 at 1:00 AM | Brownstone Research (Ad)Fractyl Health, Inc. (NASDAQ:GUTS) Receives Average Rating of "Hold" from BrokeragesMay 16, 2026 | americanbankingnews.comFractyl Health (NASDAQ:GUTS) Upgraded by Wall Street Zen to "Hold" RatingMay 16, 2026 | americanbankingnews.comA Look At Fractyl Health (GUTS) Valuation After New Gene Therapy Trial Approval And First Quarter Net IncomeMay 14, 2026 | finance.yahoo.comFractyl Health, Inc. (GUTS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 14, 2026 | seekingalpha.comFractyl Health’s Pivotal Year: Inside the Earnings CallMay 13, 2026 | tipranks.comSee More Headlines GUTS Stock Analysis - Frequently Asked Questions How have GUTS shares performed this year? Fractyl Health's stock was trading at $2.20 at the beginning of the year. Since then, GUTS stock has decreased by 58.3% and is now trading at $0.9170. How were Fractyl Health's earnings last quarter? Fractyl Health, Inc. (NASDAQ:GUTS) posted its quarterly earnings results on Tuesday, May, 12th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.23. Read the conference call transcript. When did Fractyl Health IPO? Fractyl Health (GUTS) raised $110 million in an initial public offering on Friday, February 2nd 2024. The company issued 7,333,333 shares at a price of $14.00-$16.00 per share. Who are Fractyl Health's major shareholders? Top institutional investors of Fractyl Health include Pale Fire Capital SE (3.73%), Maverick Capital Ltd. (2.51%), Bank of America Corp DE (0.08%) and OMERS ADMINISTRATION Corp (0.08%). Insiders that own company stock include Ajay Royan, Harith Rajagopalan, Jay David Caplan and William Bradley. View institutional ownership trends. How do I buy shares of Fractyl Health? Shares of GUTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Fractyl Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fractyl Health investors own include SoFi Technologies (SOFI), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Alphabet (GOOG), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/12/2026Today5/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, GUTS's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryMedical Equipment Current SymbolNASDAQ:GUTS Previous SymbolNASDAQ:GUTS CIK1572616 Webfractyl.com Phone781-902-8800FaxN/AEmployees102Year Founded2010Price Target and Rating Average Price Target for Fractyl Health$5.40 High Price Target$8.00 Low Price Target$2.00 Potential Upside/Downside+504.0%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$140.95 million Net MarginsN/A Pretax Margin-4,073,233.50% Return on Equity-4,053.15% Return on Assets-96.41% Debt Debt-to-Equity Ratio1.41 Current Ratio4.28 Quick Ratio4.28 Sales & Book Value Annual Sales$90 thousand Price / Sales1,575.92 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book6.88Miscellaneous Outstanding Shares158,650,000Free Float145,132,000Market Cap$141.83 million OptionableN/A Beta2.11 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:GUTS) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?On July 17th, the House passed the GENIUS Act - and at least one prominent Trump ally is raising alarms. Rep. ...Goldco Direct, LLC | SponsoredTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredHidden on Tesla's filing: A $12 billion "super startup"Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fractyl Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fractyl Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
